OPEN ACCESS Freely available online

Journal of Hematology & Thromboembolic Diseases

Short Communication

Targeting CD8+ Tissue Resident Memory Cells for Improved Treatment Outcomes in Idiopathic Severe Aplastic Anemia

Benjamin Lardinois*

Department of Oncology, University of the Bahamas, Nassau, Bahamas

DESCRIPTION

Idiopathic Severe Aplastic Anemia (SAA) presents a challenging clinical scenario characterized by bone marrow failure due to the immune-mediated destruction of Hematopoietic Stem and Progenitor Cells (HSPCs) [1]. While the exact mechanisms underlying this disease have remained elusive, recent advancements in single-cell RNA sequencing have shed light on a potentially pivotal player: $CD8^+$ Tissue resident memory (Trm) cells within the bone marrow microenvironment. Idiopathic SAA is believed to result from T-cell-mediated destruction of HSPCs, leading to cytopenias and compromised hematopoiesis [2-4]. Among T-cell subsets implicated in autoimmune processes, $CD8^+$ T cells have been identified as key effectors in targeting HSPCs in SAA. Specifically, a subset of $CD8^+$ Trm cells exhibiting a tissue residency phenotype has been characterized within the bone marrow of SAA patients.

Phenotypic and functional insights from single-cell RNA (Ribonucleic Acid) sequencing

Innovative approaches such as single-cell RNA sequencing of Peripheral Blood Mononuclear Cells (PBMCs) and Bone Marrow Mononuclear Cells (BMMCs) from both SAA patients and healthy donors have provided invaluable insights. This cutting-edge technique revealed a distinct $CD8^+$ Trm cell population enriched in SAA bone marrow samples. These Trm cells displayed heightened expression of Interferon-Gamma (IFN-γ) and Fas Ligand (FasL), suggesting their potential role in promoting apoptosis of HSPCs [5]. Further investigation into the mechanisms driving $CD8^+$ Trm cell differentiation uncovered a pivotal role for Interleukin-15 (IL-15) signaling, particularly presented by IL-15Rα-expressing monocytes. Notably, SAA patients exhibited an increased frequency of $CD16^+$ monocytes, which express IL-15Rα and were found to promote the differentiation of CD38+CXCR6+ precursor cells into $CD8^+$ Trm cells within the bone marrow microenvironment.

Building upon these findings, therapeutic strategies targeting IL-15-induced $CD8^+$ Trm cells present promising avenues for future treatments in SAA. The efficacy of these interventions was underscored by experiments using the CD38 inhibitor 78c, which successfully inhibited the differentiation of precursor cells into $CD8^+$ Trm cells *in vitro* [6]. Such targeted approaches highlight the potential to mitigate HSPC destruction and ameliorate disease severity in SAA patients. The discovery of IL-15-induced $CD8^+$ Trm cells as pathogenic effectors in SAA represents a significant advancement in understanding the disease's immunopathogenesis. These cells, characterized by their tissue residency and potent pro-apoptotic capabilities mediated through FasL expression, offer a compelling target for therapeutic intervention [7]. Continued research efforts should focus on elucidating the precise mechanisms by which $CD8^+$ Trm cells initiate and perpetuate HSPC destruction in SAA. This includes further exploration of IL-15 signaling pathways, the role of $CD16^+$ monocytes in Trm cell differentiation, and the development of novel inhibitors targeting these pathways. Moreover, clinical translation of these findings holds potential for developing tailored therapies that selectively target pathogenic $CD8^+$ Trm cells while preserving overall immune function. Such advancements have the potential to revolutionize treatment outcomes for SAA patients, offering hope for improved hematopoietic recovery and long-term disease management.

CONCLUSION

In conclusion, the integration of single-cell RNA sequencing and mechanistic studies has provided critical insights into the immunological landscape of SAA. By the intricate interactions driving $CD8^+$ Trm cell-mediated HSPC destruction, researchers are paving the way for more effective therapeutic strategies and ultimately, better outcomes for patients battling this challenging hematologic disorder.

Correspondence to: Benjamin Lardinois, Department of Oncology, University of the Bahamas, Nassau, Bahamas, E-mail: benjamin@lardinois.com

Received: 01-May-2024, Manuscript No JHTD-24-32019; **Editor assigned:** 03-May-2024, Pre QC No. JHTD-24-32019 (PQ); **Reviewed:** 17-May-2024, QC No. JHTD-24-32019; **Revised:** 24-May-2024, Manuscript No. JHTD-24-32019 (R); **Published:** 31-May-2024, DOI: 10.35248/2155-9554.24.12.608.

Citation: Lardinois B (2024) Targeting $CD8^+$ Tissue Resident Memory Cells for Improved Treatment Outcomes in Idiopathic Severe Aplastic Anemia. J Hematol Thrombo Dis.12:608.

REFRENCES

1. Hosokawa K, Muranski P, Feng X, Townsley DM, Liu B, Knickelbein J, et al. Memory stem T cells in autoimmune disease: High frequency of circulating CD8+ memory stem cells in acquired aplastic anemia. J Immunol. 2016;196(4):1568-1578.
2. Lin FC, Karwan M, Saleh B, Hodge DL, Chan T, Boelte KC, et al. IFN-γ causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation. Blood. 2014;124(25):3699-3708.
3. Zhang J, Liu T, Duan Y, Chang Y, Chang L, Liu C, et al. Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia. J Autoimmun. 2023;136:103026.
4. Zhu C, Lian Y, Wang C, Wu P, Li X, Gao Y, et al. Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia. Blood. 2021;138(1):23-33.
5. Kordasti S, Marsh J, Al-Khan S, Jiang J, Smith A, Mohamedali A, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012;119(9):2033-2043.
6. Muñoz P, Mittelbrunn M, de la Fuente H, Pérez-Martínez M, García-Pérez A, Ariza-Veguillas A, et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood. 2008;111(7):3653-3664.
7. Zhong H, Bao W, Li X, Miller A, Seery C, Haq N, et al. CD16+ monocytes control T-cell subset development in immune thrombocytopenia. Blood. 2012;120(16):3326-3335.